Document:

Exhibit 10.33

 

	
 

 

	
WARRANT

	
 

	
NO. CBTB __

	
 

	
_____ Shares

 

WARRANT TO PURCHASE COMMON STOCK

 

VOID AFTER 5:30 P.M., EASTERN

TIME, ON THE EXPIRATION DATE

 

THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

FOR VALUE RECEIVED, Cell Source, Inc.  a Nevada corporation (the “Company”), hereby agrees to sell upon the terms and on the conditions hereinafter set forth, but no later than 5:30 p.m., Eastern Time, on the Expiration Date (as hereinafter defined) to     ________________________ or registered assigns (the “ Holder ”), under the terms as hereinafter set forth,  _______ (_______)  fully paid and non-assessable shares of the Company’s common stock (the “Common Stock”), par value $0.001 per share (the “ Warrant Stock ”), at a purchase price of $0.75 per share (the “Warrant Price”), pursuant to this warrant (this “Warrant”). The number of shares of Warrant Stock to be so issued and the Warrant Price are subject to adjustment in certain events as hereinafter set forth. The term “Common Stock” shall mean, when used herein, unless the context otherwise requires, the stock and other securities and property at the time receivable upon the exercise of this Warrant.

 

1. Exercise of Warrant and Redemption of Warrant.

 

a. The Holder may exercise this Warrant according to its terms by surrendering this Warrant to the Company at the address set forth in Section 10, the Notice of Exercise attached hereto having then been duly executed by the Holder, accompanied by cash, certified check or bank draft in payment of the purchase price, in lawful money of the United States of America, for the number of shares of the Warrant Stock specified in the Notice of Exercise, or as otherwise provided in this Warrant, prior to 5:30 p.m., Eastern Time, on July 24, 2019 (the “ Expiration Date ”).

Notwithstanding  anything  to the  contrary  herein,  if at any time  commencing beginning  after the date of this  Warrant,  there is no effective  registration statement registering,  or no current prospectus available for the resale of the Warrant  Stock by the Holder,  then this  Warrant may also be  exercised  at the Holder's  election,  in whole or in part,  at such time by means of a  "cashless exercise"  in which the Holder  shall be entitled to receive a number of Warrant Stock equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = the 3 day VWAP on the Trading Day immediately  preceding the date on which  Holder  elects to exercise  this  Warrant by means of a "cashless exercise," as set forth in the applicable Notice of Exercise;

(B) = the Warrant Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant  Stock that would be issuable upon exercise of this Warrant in  accordance  with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

"VWAP" means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.  (based on a Trading  Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),  (b) if the OTC Bulletin  Board is not a Trading  Market or OTCQB,  the volume weighted  average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin  Board,  (c) if the Common Stock is not then listed or quoted  for  trading on the OTC  Bulletin  Board and if prices for the Common  Stock are then  reported  in the  "Pink  Sheets"  published  by Pink OTC Markets,  Inc. (or a similar  organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,  or (d) in all other cases, the fair market value of a share of Common Stock as determined by an  independent  appraiser  selected in good faith by the Board of Directors of the Company.

 

  

"Trading Day" means a day on which the principal Trading Market is open for trading.

"Trading  Market"  means the  following  markets or  exchanges on which the Common Stock is listed or quoted for trading on the date in  question:  the NYSE MKT, the Nasdaq  Capital  Market,  the Nasdaq Global  Market,  the Nasdaq Global Select Market, the New York Stock Exchange, and the OTC Markets.

This Warrant may be exercised in whole or in part so long as any exercise in part hereof would not involve the issuance of fractional shares of Warrant Stock. If exercised in part, the Company shall deliver to the Holder a new Warrant, identical in form, in the name of the Holder, evidencing the right to purchase the number of shares of Warrant Stock as to which this Warrant has not been exercised, which new Warrant shall be signed by the Chairman, Chief Executive Officer or President and the Secretary or Assistant Secretary of the Company. The term Warrant as used herein shall include any subsequent Warrant issued as provided herein.

b. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. The Company shall pay cash in lieu of fractions with respect to the Warrants based upon the fair market value of such fractional shares of Common Stock (which shall be the closing price of such shares on the exchange or market on which the Common Stock is then traded) at the time of exercise of this Warrant.

c. In the event of any exercise of the rights represented by this Warrant, a certificate or certificates for the Warrant Stock so purchased, registered in the name of the Holder, shall be delivered to the Holder within three (3) trading days after such rights shall have been so exercised (the “ Warrant Stock Delivery Date ”). The person or entity in whose name any certificate for the Warrant Stock is issued upon exercise of the rights represented by this Warrant shall for all purposes be deemed to have become the holder of record of such shares immediately prior to the close of business on the date on which the Warrant was surrendered and payment of the Warrant Price and any applicable taxes was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the opening of business on the next succeeding date on which the stock transfer books are open. The Company shall pay any and all documentary stamp or similar issue or transfer taxes payable in respect of the issue or delivery of shares of Common Stock on exercise of this Warrant.

 

d. In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder a certificate or the certificates representing the Warrant Stock pursuant to an exercise on or prior to the Warrant Stock Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Stock which the Holder anticipated receiving upon such exercise (a “ Buy-In ”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of shares of Warrant Stock that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of shares of Warrant Stock for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

e. Redemption of Warrant

 

(i) General.  Prior to the Expiration Date, the Company shall have the option, subject to the conditions set forth herein, to redeem all of the Warrants then outstanding upon not less than thirty (30) days nor more than sixty (60) days prior written notice to the Warrant Holders at any time provided that, at the time of delivery of such notice (i) there is an effective registration statement covering the resale of the Warrant Shares, and (ii) the average trading price of the Company’s Common Stock , or shares into which the Common Stock  have been exchanged, for each of the twenty (20) consecutive trading days prior to the date of the notice of redemption is at least $2.50, as proportionately adjusted to reflect any stock splits, stock dividends, combination of shares or like events, with an average daily trading volume during such period of no less than 100,000 shares.

 

(ii) Notice.  Notice of redemption will be effective upon mailing in accordance with this Section and such date may be referred to below as the “Notice Date.”  Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than 30 days prior to the date fixed for redemption to the Holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively presumed to have been duly given whether or not the Holder received such notice.

 

2

(iii) Redemption Date and Redemption Price.  The notice of redemption shall state the date set for redemption, which date shall be not less than thirty (30) days, or more than sixty (60) days, from the Notice Date (the “Redemption Date”). The Company shall not mail the notice of redemption unless all funds necessary to pay for redemption of the Warrants to be redeemed shall have first been set aside by the Company for the benefit of the Warrant Holders so as to be and continue to be available therefor. The redemption price to be paid to the Warrant Holders will be $0.01 for each share of Common Stock of the Company to which the Warrant Holder would then be entitled upon exercise of the Warrant being redeemed, as adjusted from time to time as provided herein (the “Redemption Price”).

 

(iv) Exercise.  Following the Notice Date, the Warrant Holders may exercise their Warrants in accordance with Section 1 of this Warrant between the Notice Date and 5:00 p.m. Eastern Time on the Redemption Date and such exercise shall be timely if the form of election to purchase duly executed and the Warrant Exercise Price for the shares of Common Stock to be purchased are actually received by the Company at its principal offices prior to 5:00 p.m. Eastern Time on the Redemption Date.

 

(v) Mailing. If any Warrant Holder does not wish to exercise any Warrant being redeemed, he should mail such Warrant to the Company at its principal offices after receiving the notice of redemption. On and after 5:00 p.m. Eastern Time on the Redemption Date, notwithstanding that any Warrant subject to redemption shall not have been surrendered for redemption, the obligation evidenced by all Warrants not surrendered for redemption or effectively exercised shall be deemed no longer outstanding, and all rights with respect thereto shall forthwith cease and terminate, except only the right of the holder of each Warrant subject to redemption to receive the Redemption Price for each share of Common Stock  to which he would be entitled if he exercised the Warrant upon receiving notice of redemption of the Warrant subject to redemption held by him.

 

2. Disposition of Warrant Stock and Warrant.

 

a. The Holder hereby acknowledges that this Warrant and any Warrant Stock purchased pursuant hereto are, as of the date hereof, not registered: (i) under the Securities Act of 1933, as amended (the “Securities Act”), on the ground that the issuance of this Warrant is exempt from registration under Section 4(2) of the Securities Act as not involving any public offering or (ii) under any applicable state securities law because the issuance of this Warrant does not involve any public offering; and that the Company’s reliance on the Section 4(2) exemption of the Act, as the case may be, and under applicable state securities laws is predicated in part on the representations hereby made to the Company by the Holder that it is acquiring this Warrant and will acquire the Warrant Stock for investment for its own account, with no present intention of dividing its participation with others or reselling or otherwise distributing the same, subject, nevertheless, to any requirement of law that the disposition of its property shall at all times be within its control.

The Holder hereby agrees that it will not sell or transfer all or any part of this Warrant and/or Warrant Stock unless and until it shall first have given notice to the Company describing such sale or transfer and furnished to the Company either (i) an opinion, reasonably satisfactory to counsel for the Company, of counsel (skilled in securities matters, selected by the Holder) to the effect that the proposed sale or transfer may be made without registration under the Act and without registration or qualification under any state law, or (ii) an interpretative letter from the Securities and Exchange Commission to the effect that no enforcement action will be recommended if the proposed sale or transfer is made without registration under the Act.

 

b. If, at the time of issuance of the shares issuable upon exercise of this Warrant, no registration statement is in effect with respect to such shares under applicable provisions of the Act, the Company may at its election require that the Holder provide the Company with written reconfirmation of the Holder’s investment intent and that any stock certificate delivered to the Holder of a surrendered Warrant shall bear legends reading substantially as follows:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.”

 

In addition, so long as the foregoing legend may remain on any stock certificate delivered to the Holder, the Company may maintain appropriate “stop transfer” orders with respect to such certificates and the shares represented thereby on its books and records and with those to whom it may delegate registrar and transfer functions.

 

3

3. Reservation of Shares. The Company hereby agrees that at all times there shall be reserved for issuance upon the exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance upon exercise of this Warrant. The Company further agrees that all shares which may be issued upon the exercise of the rights represented by this Warrant will be duly authorized and will, upon issuance and against payment of the exercise price, be validly issued, fully paid and non-assessable, free from all taxes, liens, charges and preemptive rights with respect to the issuance thereof, other than taxes, if any, in respect of any transfer occurring contemporaneously with such issuance and other than transfer restrictions imposed by federal and state securities laws.

 

4. Exchange, Transfer or Assignment of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations, entitling the Holder or Holders thereof to purchase in the aggregate the same number of shares of Common Stock purchasable hereunder. Upon surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax, the Company shall, without charge, execute and deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided or combined with other Warrants that carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and denominations in which new Warrants are to be issued and signed by the Holder hereof.

5. Capital Adjustments. This Warrant is subject to the following further provisions:

 

a. Intentionally Omitted.

 

b. Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its Common Stock, the number of shares of Warrant Stock purchasable upon exercise of this Warrant and the Warrant Price shall be proportionately adjusted.

 

c. Stock Dividends and Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall issue or pay the holders of its Common Stock, or take a record of the holders of its Common Stock for the purpose of entitling them to receive, a dividend payable in, or other distribution of, Common Stock, then (i) the Warrant Price shall be adjusted in accordance with Section 5(f) and (ii) the number of shares of Warrant Stock purchasable upon exercise of this Warrant shall be adjusted to the number of shares of Common Stock that the Holder would have owned immediately following such action had this Warrant been exercised immediately prior thereto.

 

d. Stock and Rights Offering to Shareholders. If the Company shall at any time after the date of issuance of this Warrant distribute to all holders of its Common Stock any shares of capital stock of the Company (other than Common Stock) or evidences of its indebtedness or assets (excluding cash dividends or distributions paid from retained earnings or current year’s or prior year’s earnings of the Company) or rights or warrants to subscribe for or purchase any of its securities (excluding those referred to in the immediately preceding paragraph) (any of the foregoing being hereinafter in this paragraph called the “Securities”), then in each such case, the Company shall reserve shares or other units of such Securities for distribution to the Holder upon exercise of this Warrant so that, in addition to the shares of the Common Stock to which such Holder is entitled, such Holder will receive upon such exercise the amount and kind of such Securities which such Holder would have received if the Holder had, immediately prior to the record date for the distribution of the Securities, exercised this Warrant.

e. Intentionally Omitted.

 

f. Warrant Price Adjustment. Except as otherwise provided herein, whenever the number of shares of Warrant Stock purchasable upon exercise of this Warrant is adjusted, as herein provided, the Warrant Price payable upon the exercise of this Warrant shall be adjusted to that price determined by multiplying the Warrant Price immediately prior to such adjustment by a fraction (i) the numerator of which shall be the number of shares of Warrant Stock purchasable upon exercise of this Warrant immediately prior to such adjustment, and (ii) the denominator of which shall be the number of shares of Warrant Stock purchasable upon exercise of this Warrant immediately thereafter.

 

g. Certain Shares Excluded. The number of shares of Common Stock outstanding at any given time for purposes of the adjustments set forth in this Section 5 shall exclude any shares then directly or indirectly held in the treasury of the Company.

 

h. Deferral and Cumulation of De Minimis Adjustments. The Company shall not be required to make any adjustment pursuant to this Section 5 if the amount of such adjustment would be less than one percent (1%) of the Warrant Price in effect immediately before the event that would otherwise have given rise to such adjustment. In such case, however, any adjustment that would otherwise have been required to be made shall be made at the time of and together with the next subsequent adjustment which, together with any adjustment or adjustments so carried forward, shall amount to not less than one (1%) percent of the Warrant Price in effect immediately before the event giving rise to such next subsequent adjustment.

 

4

i. Duration of Adjustment. Following each computation or readjustment as provided in this Section 5, the new adjusted Warrant Price and number of shares of Warrant Stock purchasable upon exercise of this Warrant shall remain in effect until a further computation or readjustment thereof is required.

 

6. Limitation on Exercises.

 

a. Notwithstanding anything to the contrary set forth in this Warrant, at no time may all or a portion of the Warrant be exercised if the number of shares of Common Stock to be issued pursuant to such exercise would exceed, when aggregated with all other shares of Common Stock owned by the Holder at such time, the number of shares of Common Stock which would result in the Holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules thereunder) more than 4.99% of all of the Common Stock outstanding at such time; provided , however , that upon the Holder providing the Corporation with sixty-one (61) days’ advance notice (the “4.99% Waiver Notice”) that the Holder would like to waive this Section 6 (a) with regard to any or all shares of Common Stock issuable upon exercise of this Warrant, this Section 6 (a) will be of no force or effect with regard to all or a portion of this Warrant referenced in the 4.99% Waiver Notice.

 

b. Notwithstanding anything to the contrary set forth in this Warrant, at no time may all or a portion of this Warrant be exercised if the number of shares of Common Stock to be issued pursuant to such exercise, when aggregated with all other shares of Common Stock owned by the Holder at such time, would result in the Holder beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act and the rules thereunder) in excess of 9.99% of the then issued and outstanding shares of Common Stock outstanding at such time (the “ 9.99% Beneficial Ownership Limitation ” and the lower of the 9.99% Beneficial Ownership Limitation and the 4.99% Beneficial Ownership Limitation then in effect, the “ Maximum Percentage ”).

 

c. By written notice to the Company, the Holder may from time to time decrease the Maximum Percentage to any other percentage specified in such notice

 

d. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company's most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company setting forth the number of shares of Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) business day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 6 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.

 

7. Notice to Holders.

 

a. Notice of Record Date. In case:

 

(i) the Company shall take a record of the holders of its Common Stock (or other stock or securities at the time receivable upon the exercise of this Warrant) for the purpose of entitling them to receive any dividend (other than a cash dividend payable out of earned surplus of the Company) or other distribution, or any right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right;

 

(ii) of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation with or merger of the Company into another corporation, or any conveyance of all or substantially all of the assets of the Company to another corporation; or

 

(iii) of any voluntary dissolution, liquidation or winding-up of the Company;

 

then, and in each such case, the Company will mail or cause to be mailed to the Holder hereof at the time outstanding a notice specifying, as the case may be, (i) the date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which such reorganization, reclassification, consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the time, if any, is to be fixed, as of which the holders of record of Common Stock (or such stock or securities at the time receivable upon the exercise of this Warrant) shall be entitled to exchange their shares of Common Stock (or such other stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, conveyance, dissolution or winding-up. Such notice shall be mailed at least thirty (30) days prior to the record date therein specified, or if no record date shall have been specified therein, at least thirty (30) days prior to such specified date, provided, however, failure to provide any such notice shall not affect the validity of such transaction.

 

5

b. Certificate of Adjustment. Whenever any adjustment shall be made pursuant to Section 5 hereof, the Company shall promptly make a certificate signed by its Chairman, Chief Executive Officer, President, Vice President, Chief Financial Officer or Treasurer, setting forth in reasonable detail the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated and the Warrant Price and number of shares of Warrant Stock purchasable upon exercise of this Warrant after giving effect to such adjustment, and shall promptly cause copies of such certificates to be mailed (by first class mail, postage prepaid) to the Holder of this Warrant.

 

8. Loss, Theft, Destruction or Mutilation. Upon receipt by the Company of evidence satisfactory to it, in the exercise of its reasonable discretion, of the ownership and the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, of indemnity reasonably satisfactory to the Company and, in the case of mutilation, upon surrender and cancellation thereof, the Company will execute and deliver in lieu thereof, without expense to the Holder, a new Warrant of like tenor dated the date hereof.

 

9. Warrant Holder Not a Stockholder. The Holder of this Warrant, as such, shall not be entitled by reason of this Warrant to any rights whatsoever as a stockholder of the Company.

 

10. Notices. Any notice required or contemplated by this Warrant shall be deemed to have been duly given if transmitted by registered or certified mail, return receipt requested, or nationally recognized overnight delivery service, to the Company at its principal executive offices, Attn: Chief Executive Officer, or to the Holder at the name and address set forth in the Warrant Register maintained by the Company.

 

11. Choice of Law. THIS WARRANT IS ISSUED UNDER AND SHALL FOR ALL PURPOSES BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAW.

 

12. Jurisdiction and Venue. The Company and Holder hereby agree that any dispute which may arise between them arising out of or in connection with this Warrant shall be adjudicated before a court located in New York County, New York and they hereby submit to the exclusive jurisdiction of the federal and state courts of the State of York located in New York County with respect to any action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum, relating to or arising out of this Warrant or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action or legal proceeding by means of registered or certified mail, return receipt requested, in care of the address set forth herein or such other address as either party shall furnish in writing to the other.

 

13. Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent signed by both (a) the Company and (b) holders of Warrants representing a majority of the Warrant Stock then outstanding and not exercised

[Signature Page Follows]

6

 

IN WITNESS WHEREOF, the Company has duly caused this Warrant to be signed on its behalf, in its corporate name and by its duly authorized officers, as of this __ day of July, 2016.

 

	 	
By:

	 	
Name: Itamar Shimrat

	 	
Title: CEO

 

  

7

 

NOTICE OF EXERCISE

 

TO: ________________________________________

Tel: (___) ___-____

Fax: (___) ___-____

 

 

(1) The undersigned hereby elects to purchase ______________ shares of Warrant Stock of the Company pursuant to the terms of the attached Warrant to Purchase Common Stock, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment shall take the form of:

 

£ in lawful money of the United States

 

Please issue a certificate or certificates representing said shares of Warrant Stock in the name of the undersigned or in such other name as is specified below:

 

________________________________________________________________________________________________________________________________

 

The shares of Warrant Stock shall be delivered to the following DWAC Account Number, if permitted, or by physical delivery of a certificate to:

 

________________________________________________________________________________________________________________________________

 

(3) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

Signature of Authorized Signatory of Investing Entity:

 

Name and Title of Authorized Signatory:

 

Date:

 

8

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

 

 this form and supply required information.

 Do not use this form to exercise the warrant.)

FOR VALUE RECEIVED, all of or _________ shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

________________________________whose address is

_____________________________________________

_____________________________________________

Dated:  _________,         

 

Holder’s Name:

 

Holder’s Signature:

 

Name and Title of Signatory:

 

Holder’s Address:

 

Signature Guaranteed:

 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

 

9Exhibit 10.34

 

SECOND AMENDMENT TO RESEARCH AND LICENCE AGREEMENT

(this “Amendment”)

Effective Date: November 28, 2016

By and between

YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED

a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel

(hereinafter, “Yeda”)

and

CELL SOURCE LIMITED

a company duly registered under the laws of Israel of 5 Kineret Street, Bnei Brak  5126237

(hereinafter, “Cell Source”)

	WHEREAS	
Yeda and Cell Source are parties to a research and licence agreement dated October 3rd, 2011, as amended by a first amendment thereto dated April 8, 2014 (together, "the R&L Agreement”); and

	WHEREAS	
Cell Source has notified Yeda in writing that it does not wish to exercise its option rights under the Evaluation and Exclusive License Agreement between the parties dated October 3rd, 2011 (as amended from time to time), and the parties wish to amend the R&L Agreement accordingly; and

	WHEREAS	
the parties also wish to update Appendix A (Patent Cards) of the R&L Agreement, to amend the development milestones and to make certain additional amendments to the R&L Agreement, all subject to the terms and conditions set out in this Amendment below.

NOW THEREFORE IT IS AGREED BY THE PARTIES HERETO AS FOLLOWS:

	1.	
Terms and phrases used in this Amendment which are defined in the R&L Agreement shall have in this Amendment the same meaning as that attributed to them in the R&L Agreement, unless otherwise expressly defined in this Amendment.

	2.	
This Amendment and the R&L Agreement shall be read as one and shall represent the complete current understanding between the parties with respect to the subject matter hereof. Subject to the modifications contained herein, the provisions of the R&L Agreement shall remain unaltered and in full force and effect.

	3.	
The above preamble forms an integral part of this Amendment.

 

 

	
4.

	
The R&L Agreement shall be modified, as of the Effective Date, as follows:

	4.1	
In the first paragraph of the preamble thereto, the numbers “2000-017, 2005-082, 2008-108, 2010-071, 2010-073, 2011-077” shall be deleted and replaced by the following: “2000-017, 2008-108, 2010-073, 2011-077, 2011-095, 2015-049, 2015-062, 2016-027” and Appendix A to the R&L Agreement shall be replaced in its entirety by Annex A of this Amendment;

	4.2	
The final paragraph of the preamble thereto (including Appendix 1 thereto which is referenced in said paragraph) shall be deleted in its entirety;

	4.3	
Clause 3 thereto shall be amended such that the words: “provided that, in the event the a R&L Agreement shall be executed between the parties in accordance of the E&O Agreement (as amended), then the annual Research Budget in respect of the Research Period shall, beginning on the date such R&L Agreement shall be signed, be an amount of US$ 900,000 (nine hundred thousand US Dollars) per year” shall be deleted;

	4.4	
The final paragraph of clause 3 thereto shall be deleted in its entirety and replaced by the following:

“In addition to the sums detailed in this clause 3 above, within 7 (seven) days of the achievement of the Company of the receipt of an aggregate total equity capital investment in the Company of more than $10,000,000 (ten million US dollars), the Company shall pay Yeda a non-refundable payment in the sum of US $200,000 (two hundred thousand US Dollars) (the “Additional Research Payment”). The Additional Research Payment shall be allocated by Yeda to support research activities of the Scientist under this Agreement according to an additional Research plan to be submitted to the Company by Yeda.

	4.5	
In clause 4 thereto, the words “3 (three) month” shall be deleted wherever they appear and replaced by the words “6 (six) month”;

	4.6	
Clause 13.2.1 shall be deleted in its entirety and replaced by the following:

		“13.2.1	
If the Company fails to achieve any one of the milestones set forth in sub-clauses (a) to (e) below by the dates specified therefor, Yeda shall be entitled, at its option: (i) to modify the Licence hereunder so that it is non-exclusive only, by written notice to the Company (any such amendment of this Agreement by Yeda as aforesaid, being effective immediately, the Company’s consent thereto (written or otherwise) not being required, notwithstanding the provisions of clause 17.2 below); or (ii) to terminate this Agreement (including the Licence hereunder) by giving the Company 30 (thirty) days’ written notice:

(a) by January 1, 2018, to have successfully filed a pre-IND application in respect of a Product with the FDA or other equivalent regulatory agency in another country;

(b) by January 1, 2021, to have commenced Phase II clinical trials in a respect of a Product;

 

2

(c) by July 1, 2023, to have either commenced Phase III clinical trials or to have received FDA or EMA marketing approval in a respect of a Product (“Marketing Approval”);

(d) within 12 (twelve) months from the date of Marketing Approval, to have made a First Commercial Sale of a Product; or

(e) in case commercial sale of any Product having commenced, there shall be a period of 12 (twelve) months or more during which no sales of any Product shall take place by the Company or its Sublicensees (except as a result of force majeure or other factors beyond the control of the Company).";

	4.7	
In clause 13 thereto, the words “which has not been cured by the party in breach within 21 (twenty-one) days (or, in the case of failure by the Company to pay any amount due from the Company to Yeda pursuant to or in connection with this Agreement on or before the due date of payment, 10 (ten) days)” shall deleted and replaced by the words: “which has not been cured by the party in breach within 30 (thirty) days”;

and

	4.8	
Yeda’s bank details in clause 17.7 thereto shall deleted and replaced by the following: “Bank Leumi le–Israel B.M., Rehovot business branch, 2 Ilan Ramon Street, Ness Ziona, branch #978, account no. 6370094; swift: LUMIILITTLV, Routing Number: IL010978, IBAN no. IL7401 09780 0000 0637 0094”.

	
5.

	
For the avoidance of doubt, this Amendment constitutes the entire agreement between the parties hereto in respect of the subject matter hereof, and supersede all prior agreements or understandings between the parties relating to the subject matter hereof (including any previous correspondence in this regard, between the parties, or on their behalf) and may be amended only by a written document signed by both parties hereto.

[signature page follows]

  

3

IN WITNESS WHEREOF the parties hereto have set their signatures as of the Effective Date.

	
For    YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED

	 	
For    CELL SOURCE LIMITED

	 	 	 	 	 
	
Signature:

	
/s/ Mudl Sheves

/s/ Gil Granot-Mayor

	 	
Signature:

	
/s/ Itamar Shimrat

	 	 	 	 	 
	
Name

	
Prof. Mudl Sheves

Gil-Granot-Mayor

	 	
Name:

	
Itamar Shimrat

	
Title

	
Chairman

 CEO

	 	
Title:

	
Chief Executive Officer

4

Annex A – Updated Patent Cards

 

PATENT CARD

 

2000-017

 

Title: VETO CELLS EFFECTIVE IN PREVENTING GRAFT REJECTION AND DEVOID OF GRAFT VERSUS HOST POTENTIAL

 

Inventors: REISNER Yair, MARTELLI Massimo

 

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
05/01/2000 - 09/477,737

	
-

	
6,544,506 - 08/04/2003

	
Granted

	
PCT

	
28/12/2000 - PCT/IL00/00872

	
12/07/2001 - WO 01/49243

	
-

	
Published

	
European Patent Office

	
28/12/2000 - 00983473.0

	
02/10/2002 - 1 244 803

	
1 244 803 - 22/02/2006

	
Validated

	
   France

	
28/12/2000 - 00983473.0

	
-

	
1 244 803 - 22/02/2006

	
Granted

	
   Germany

	
28/12/2000 - 00983473.0

	
-

	
60026166.2 - 22/02/2006

	
Granted

	
   Italy

	
28/12/2000 - 00983473.0

	
-

	
1 244 803 - 22/02/2006

	
Granted

	
   Switzerland

	
28/12/2000 - 00983473.0

	
-

	
1 244 803 - 22/02/2006

	
Granted

	
   United Kingdom

	
28/12/2000 - 00983473.0

	
-

	
1 244 803 - 22/02/2006

	
Granted

	
Israel

	
28/12/2000 - 150440

	
-

	
150440 - 31/03/2011

	
Granted

	
U.S.A

	
28/12/2000 - 10/169,028

	
-

	
7,270,810 - 18/09/2007

	
Granted

 

PATENT CARD

 

2008-108

 

Title: ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT

 

Inventors: REISNER Yair, OPHIR Eran, EIDELSTEIN Yaki, BACHAR-LUSTIG Esther

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
30/10/2008 - 61/193,137

	
-

	
-

	
Expired

	
U.S.A

	
12/06/2009 - 61/213,482

	
-

	
-

	
Expired

	
PCT

	
29/10/2009 - PCT/IL2009/001014

	
06/05/2010 - WO 2010/049935

	
-

	
Published

	
China

	
29/10/2009 - 200980153053.4

	
07/12/2011 - 102271702

	
ZL200980153053.4 - 25/11/2015

	
Granted

	
European Patent Office

	
29/10/2009 - 09764302.7

	
21/09/2011 - 2 365 823

	
-

	
Pending

	
India

	
29/10/2009 - 905/MUMNP/2011

	
-

	
-

	
Pending

	
Israel

	
29/10/2009 - 212587

	
-

	
212587 - 01/04/2016

	
Granted

	
Russian Federation

	
29/10/2009 - 2011121630

	
-

	
2506311 - 10/02/2014

	
Granted

	
U.S.A

	
29/10/2009 - 13/126,472

	
01/09/2011 - 2011-0212071

	
-

	
Pending

 

5

 

PATENT CARD

 

2010-073

 

Title: USE OF ANTI THIRD PARTY CENTRAL MEMORY T CELLS FOR ANTI-LEUKEMIA/LYMPHOMA TREATMENT

 

Inventors: REISNER Yair, LASK Assaf, OPHIR Eran, OR-GEVA Noga, COHEN Adva

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
08/09/2010 - 61/380,716

	
-

	
-

	
Expired

	
PCT

	
08/09/2011 - PCT/IL2011/000727

	
15/03/2012 - WO 2012/032526

	
-

	
Published

	
Brazil

	
08/09/2011 - BR 11 2013 005756 4

	
31/12/2013 - BR 11 2013 005756 4

	
-

	
Published

	
Canada

	
08/09/2011 - 2,810,632

	
-

	
-

	
Pending

	
China

	
08/09/2011 - 201610307275.9

	
31/08/2016 - CN 105907713 A

	
-

	
Published

	
China

	
08/09/2011 - 201180053858.9

	
04/09/2013 - CN 103282047 A

	
ZL201180053858.9 - 24/08/2016

	
Granted

	
European Patent Office

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Validated

	
   Austria

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Belgium

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Czech Republic

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   France

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Germany

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Greece

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Hungary

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Ireland

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Italy

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Poland

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Portugal

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Spain

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Sweden

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Switzerland

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   The Netherlands

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   Turkey

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

	
   United Kingdom

	
08/09/2011 - 11773325.3

	
17/07/2013 - 2 613 801

	
2 613 801 - 08/06/2016

	
Granted

 

6

 

 

	
Hong Kong

	
08/09/2011 - 14100513.2

	
-

	
-

	
Allowed

	
Israel

	
08/09/2011 - 225102

	
-

	
-

	
Pending

	
Japan

	
08/09/2011 - 2013-527738

	
30/09/2013 - P2013-537187A

	
5,977,238 - 29/07/2016

	
Granted

	
Korea

	
08/09/2011 - 2013-7008892

	
-

	
-

	
Pending

	
Mexico

	
08/09/2011 - MX/a/2013/002668

	
-

	
-

	
Pending

	
Singapore

	
08/09/2011 - 201301743-9

	
-

	
188473 - 26/01/2016

	
Granted

	
U.S.A

	
08/09/2011- 15/242,666

	
-

	
-

	
Pending

	
U.S.A

	
08/09/2011 - 13/821,255

	
04/07/2013 - 2013-0171108-A1

	
9,421,228 - 23/08/2016

	
Granted

PATENT CARD

 

2011-077

 

Title: ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT

 

Inventors: REISNER Yair, EIDELSTEIN Yaki, OPHIR Eran, LASK Assaf, AFIK Ran, BACHAR-LUSTIG Esther, OR-GEVA Noga

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
08/09/2011 - 61/532,172

	
-

	
-

	
Expired

	
PCT

	
06/09/2012 - PCT/IL2012/050354

	
14/03/2013 - WO 2013/035099

	
-

	
Published

	
Australia

	
06/09/2012 - 20120305931

	
-

	
-

	
Pending

	
Brazil

	
06/09/2012 - BR 11 2014 005355 3

	
21/10/2014 -

	
-

	
Published

	
Canada

	
06/09/2012 - 2,848,121

	
-

	
-

	
Pending

	
China

	
06/09/2012 - 201280054739.X

	
16/07/2014 - CN 103930130 A

	
201280054739.X - 06/06/2016

	
Granted

	
European Patent Office

	
06/09/2012 - 12769743.1

	
16/07/2014 - 2753351

	
-

	
Pending

	
Hong Kong

	
06/09/2012 - HK 15100534.6

	
31/07/2015 - 1200099A

	
-

	
Published

	
India

	
06/09/2012 - 577/MUMNP/2014

	
-

	
-

	
Pending

	
Israel

	
06/09/2012 - 231397

	
-

	
-

	
Pending

	
Japan

	
06/09/2012 - 2014-529143

	
06/10/2014 - P2014-526244A

	
-

	
Published

	
Korea

	
06/09/2012 - 10-2014-7009267

	
23/07/2014 - 10-2014-0092298

	
-

	
Published

	
Mexico

	
06/09/2012 - MX/a/2014/002771

	
-

	
-

	
Pending

	
New Zealand

	
06/09/2012 - 622749

	
-

	
622749 - 02/02/2016

	
Granted

	
Russian Federation

	
06/09/2012 - 2014110897

	
-

	
-

	
Pending

	
Singapore

	
06/09/2012 - 11201400513P

	
-

	
-

	
Pending

	
South Africa

	
06/09/2012 - 2014/01993

	
19/09/2014 -

	
-

	
Allowed

	
U.S.A

	
06/09/2012 - 14/343,053

	
31/07/2014 - 2014-0212398

	
-

	
Pending

  

7

PATENT CARD

 

2011-095

 

Title: A COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT USING SPECIFIC PROTOCOLS FOR T/B CELL DEPLETION

 

Inventors: REISNER Yair, BACHAR-LUSTIG Esther

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
22/12/2011 - 61/578,917

	
-

	
-

	
Expired

	
PCT

	
20/12/2012 - PCT/IL2012/050542

	
27/06/2013 - WO 2013/093920

	
-

	
Published

	
PCT

	
20/12/2012 - PCT/IL2012/050541

	
27/06/2013 - WO 2013/093919

	
-

	
Published

	
Australia

	
20/12/2012 - 2012355990

	
-

	
-

	
Pending

	
Australia

	
20/12/2012 - 2012355989

	
-

	
-

	
Pending

	
Brazil

	
20/12/2012 - BR 11 2014 015960 2

	
21/10/2014 -

	
-

	
Pending

	
Brazil

	
20/12/2012 - BR 11 2014 015959 9

	
-

	
-

	
Pending

	
Canada

	
20/12/2012 - 2,859,953

	
27/06/2013 -

	
-

	
Pending

	
Canada

	
20/12/2012 - 2,859,952

	
27/06/2013 -

	
-

	
Pending

	
China

	
20/12/2012 - 201280068202.9

	
25/03/2015 - CN 104470542 A

	
-

	
Pending

	
China

	
20/12/2012 - 201280068917.4

	
08/10/2014 - CN 104093314 A

	
-

	
Pending

	
European Patent Office

	
20/12/2012 - 12859036.1

	
29/10/2014 - 2793914

	
-

	
Pending

	
European Patent Office

	
20/12/2012 - 12861023.5

	
05/11/2014 - 2797421

	
-

	
Pending

	
Hong Kong

	
20/12/2012 - 15103467.1

	
09/10/2015 - 1202810A

	
-

	
Published

	
Hong Kong

	
20/12/2012 - 15103468.0

	
09/10/2015 - 1202775A

	
-

	
Published

	
India

	
20/12/2012 - 1468/MUMNP/2014

	
27/06/2013 -

	
-

	
Pending

	
India

	
20/12/2012 - 1467/MUMNP/2014

	
27/06/2013 -

	
-

	
Pending

	
Israel

	
20/12/2012 - 233303

	
27/06/2013 - WO 2013/093920

	
-

	
Pending

	
Israel

	
20/12/2012 - 233302

	
27/06/2013 - WO 2013/093919

	
-

	
Pending

	
Japan

	
20/12/2012 - 2014-548337

	
05/02/2015 - P2015-504047A

	
-

	
Pending

	
Japan

	
20/12/2012 - 2014-548336

	
22/01/2015 - 2015-502401

	
-

	
Pending

	
Korea

	
20/12/2012 - 10-2014-702449

	
04/09/2014 - 10-2014-0107564

	
2014/05071 - 25/11/2015

	
Granted

	
Korea

	
20/12/2012 - 10-2014-7020448

	
02/09/2014 - 10-2014-0105848

	
-

	
Published

	
Mexico

	
20/12/2012 - Mx/a/2014/007647

	
-

	
-

	
Pending

	
Mexico

	
20/12/2012 - Mx/a/2014/007648

	
27/06/2013 - WO 2013/093919

	
-

	
Pending

	
New Zealand

	
20/12/2012 - 627272

	
-

	
-

	
Pending

	
New Zealand

	
20/12/2012 - 627549

	
-

	
-

	
Pending

 

8

 

 

	
Russian Federation

	
20/12/2012 - 2014128479

	
-

	
-

	
Pending

	
Russian Federation

	
20/12/2012 - 2014129632

	
27/06/2013 - WO 2013/093919

	
-

	
Pending

	
Singapore

	
20/12/2012 - 11201403459X

	
-

	
-

	
Pending

	
Singapore

	
20/12/2012 - 11201403456U

	
-

	
11201403456U - 08/06/2016

	
Granted

	
South Africa

	
20/12/2012 - 2014/05071

	
-

	
2014/05071 - 25/11/2015

	
Granted

	
South Africa

	
20/12/2012 - 2014/05298

	
-

	
2014/05298 - 25/11/2015

	
Granted

	
U.S.A

	
20/12/2012 - 14/367,923

	
18/12/2014 - 2014-0369974

	
-

	
Published

	
U.S.A

	
20/12/2012 - 14/367,917

	
11/12/2014 - 2014-0363437

	
-

	
Published

PATENT CARD

 

2015-049

 

Title: USE OF ANTI THIRD PARTY CENTRAL MEMORY T CELLS

 

Inventors: OR-GEVA Noga, OPHIR Eran, REISNER Yair, EIDELSTEIN Yaki, GIDRON Rotem

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
16/07/2015 - 62/193,207

	
-

	
-

	
Expired

	
PCT

	
14/07/2016 - PCT/IL2016/050774

	
-

	
-

	
Pending

PATENT CARD

 

2015-062

 

Title: GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY

 

Inventors: OR-GEVA Noga, OPHIR Eran, REISNER Yair, EIDELSTEIN Yaki, GIDRON Rotem

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
16/07/2015 - 62/193,207

	
-

	
-

	
Expired

	
PCT

	
14/07/2016 -

	
-

	
-

	
Pending

PATENT CARD

 

2016-027

 

Title: VETO CELLS GENERATED FROM MEMORY T CELLS

 

Inventors: REISNER Yair, OR-GEVA Noga, GIDRON Rotem, BACHAR-LUSTIG Esther, LASK Assaf, KAGAN Sivan

	
Country

	
Application

	
Publication

	
Grant

	
Status

	 	 	 	 	 
	
U.S.A

	
27/06/2016 -

	
-

	
-

	
Pending

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]